JPRN-jRCT2031230602招募中2 期
A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint or the main data analysis or has been stopped prematurely.
Tanigawa Takahiko0 个研究点目标入组 1 人开始时间: 2024年1月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 10age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving regorafenib as study treatment.
- •- Participant is currently benefiting from treatment with regorafenib monotherapy. All participants must meet criteria to initiate a subsequent cycleof therapy, as determined by the guidelines of the feeder protocol.
- •- Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and notrequiring further treatment interruption by the investigator.
排除标准
- •- Ineligibility, for medical reasons, to start the subsequent cycle in the respective feeder study.
- •- Participants with a beta-human chorionic gonadotropin (hCG) test result consistent with pregnancy.
- •- Participants are using one or more of the prohibited medications listed in the respective feeder study protocol.
- •- Participant has been previously permanently discontinued from regorafenib treatment.
研究者
相似试验
进行中（未招募）
1 期
Regorafenib rollover study1. metastatic or unresectable renal cell cancer (RCC) 2. metastatic and/or unresectable gastrointestinal stromal tumors (GIST) 3. metastatic colorectal cancer (CRC) 4. hepatocellular carcinoma (HCC)MedDRA version: 20.0 Level: LLT Classification code 10038407 Term: Renal cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003650-24-GBBayer AG15
已完成
4 期
A clinical study of regorafenib in participants who have been treated in previous Bayer-sponsored regorafenib studies that have been completedhepatocellular carcinomaJPRN-jRCT1080224680Bayer Yakuhin, Ltd.50
进行中（未招募）
1 期
Regorafenib rollover study1.metastatic or unresectable renal cell cancer (RCC)2.metastatic and/or unresectable gastrointestinal stromal tumors (GIST)3.metastatic colorectal cancer (CRC)4.hepatocellular carcinoma (HCC)MedDRA version: 21.1Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864EUCTR2018-003650-24-ITBAYER AG15
进行中（未招募）
1 期
Regorafenib rollover studyEUCTR2018-003650-24-DEBayer AG15
已完成
2 期
A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell LymphomaRefractory or relapsed (relapse after transplant or relapse after medication in patients ineligible for transplant) diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) or High-grade B cell lymphomaJPRN-jRCT1080223858Gilead Sciences K.K.10